Literature DB >> 23839028

Abuse liability of novel 'legal high' designer stimulants: evidence from animal models.

Lucas R Watterson1, Elizabeth Watterson, Michael Foster Olive.   

Abstract

In the last few years, the variety and recreational use of 'legal high' designer stimulants has increased to unprecedented levels. Since their rapid emergence in drug markets, numerous adverse physical and psychological effects have been extensively reported. However, less is understood about the potential for compulsive use of and addiction to these drugs. Recently, a small collection of scientific studies assessing the abuse liability of these drugs has emerged. This new knowledge has been derived primarily from animal studies using behaviorally based procedures which include intravenous self-administration, conditioned place preference, intracranial self-stimulation, and drug discrimination. In this review we present a brief history of the recent rise in designer stimulant use followed by a short methodological description of the aforementioned procedures. We then review neurochemical and abuse liability studies on designer stimulants that have been examined to date. Finally, we conclude with a discussion of these collective findings, our current understanding of the abuse liability of these drugs in relation to each other and the illicit drugs they are designed to mimic, and recommend future research directions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23839028      PMCID: PMC6661301          DOI: 10.1097/FBP.0b013e3283641ec8

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  6 in total

1.  Synthetic cathinones and their rewarding and reinforcing effects in rodents.

Authors:  Lucas R Watterson; M Foster Olive
Journal:  Adv Neurosci (Hindawi)       Date:  2014-06-04

Review 2.  Baths salts, spice, and related designer drugs: the science behind the headlines.

Authors:  Michael H Baumann; Ernesto Solis; Lucas R Watterson; Julie A Marusich; William E Fantegrossi; Jenny L Wiley
Journal:  J Neurosci       Date:  2014-11-12       Impact factor: 6.167

3.  Atypical dopamine efflux caused by 3,4-methylenedioxypyrovalerone (MDPV) via the human dopamine transporter.

Authors:  Aparna Shekar; Jenny I Aguilar; Greta Galli; Nicholas V Cozzi; Simon D Brandt; Arnold E Ruoho; Michael H Baumann; Heinrich J G Matthies; Aurelio Galli
Journal:  J Chem Neuroanat       Date:  2017-02-03       Impact factor: 3.052

Review 4.  Neuropharmacology of 3,4-Methylenedioxypyrovalerone (MDPV), Its Metabolites, and Related Analogs.

Authors:  Michael H Baumann; Mohammad O Bukhari; Kurt R Lehner; Sebastien Anizan; Kenner C Rice; Marta Concheiro; Marilyn A Huestis
Journal:  Curr Top Behav Neurosci       Date:  2017

5.  Awash in a sea of 'bath salts': implications for biomedical research and public health.

Authors:  Michael H Baumann
Journal:  Addiction       Date:  2014-07-01       Impact factor: 6.526

6.  Effects of α-pyrrolidinopentiophenone and 4-methyl-N-ethylcathinone, two synthetic cathinones commonly found in second-generation "bath salts," on intracranial self-stimulation thresholds in rats.

Authors:  Lucas R Watterson; Brian T Burrows; Raymundo D Hernandez; Katherine N Moore; Megan Grabenauer; Julie A Marusich; M Foster Olive
Journal:  Int J Neuropsychopharmacol       Date:  2014-10-31       Impact factor: 5.176

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.